Personal information

Activities

Collapse all

Works (5)

Fremanezumab in real-life clinical practice: specialized headache center experience

Neurology, Neuropsychiatry, Psychosomatics
2024-06-22 | Journal article
DOI: 10.14412/2074-2711-2024-3-72-78
Contributors: Yu. E. Azimova; K. V. Skorobogatikh; V. V. Osipova; D. Z. Korobkova; N. V. Vashchenko; E. Z. Mamkhegov; A. S. Galanina; E. A. Guziy
Source: check_circle
Crossref

Influence of significant stressful events on the course of primary cephalalgia

Russian Journal of Pain
2023 | Journal article
DOI: 10.17116/pain20232101126
Contributors: Yu.E. Azimova; K.V. Skorobogatykh; V.V. Osipova; M.L. Kukushkin; D.Z. Korobkova; N.V. Vashchenko; A.M. Uzhakhov; S.Yu. Kornienko; E.Z. Mamkhegov
Source: check_circle
Crossref

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data

Meditsinskiy sovet = Medical Council
2022-01-06 | Journal article
DOI: 10.21518/2079-701X-2021-21-1-64-70
Contributors: N. V. Vashchenko; A. M. Uzhakhov; M. V. Bogorodskaya; D. Z. Korobkova; Ju. E. Azimova; K. V. Skorobogatykh
Source: check_circle
Crossref

Efficacy and safety of anti-CGRP(r) monoclonal antibodies in real clinical practice: preliminary analysis after three months of therapy

Neurology, Neuropsychiatry, Psychosomatics
2021-12-15 | Journal article
DOI: 10.14412/2074-2711-2021-6-62-66
Contributors: V. N. Vashchenko; D. Z. Korobkova; K. V. Skorobogatykh; Yu. E. Azimova
Source: check_circle
Crossref

Anti-CGRP monoclonal antibodies: a breakthrough in the treatment of migraine

Journal of Neurology & Stroke
2019-09-12 | Journal article
DOI: 10.15406/jnsk.2019.09.00387
Contributors: Julia Azimova; Yaroslav Ashikhmin; Mikhail Kukushkin; Aleksandr Amelin; Eugene Klimov; Kirill Skorobogatykh
Source: check_circle
Crossref
How many people are using ORCID?